Loading
HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.
HST-1011 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by HotSpot Therapeutics, Inc, in metastatic cancer. Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording.
1.HST-1011 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HST-1011" OR ABSTRACT:"HST-1011" OR TITLE:"CBL-B inhibitor" OR ABSTRACT:"CBL-B inhibitor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HST-1011, not a curated reading list.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.